EA201000391A1 - Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция - Google Patents

Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция

Info

Publication number
EA201000391A1
EA201000391A1 EA201000391A EA201000391A EA201000391A1 EA 201000391 A1 EA201000391 A1 EA 201000391A1 EA 201000391 A EA201000391 A EA 201000391A EA 201000391 A EA201000391 A EA 201000391A EA 201000391 A1 EA201000391 A1 EA 201000391A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
pharmaceutical composition
inhibitor
glycogenphosphorylase
representing itself
Prior art date
Application number
EA201000391A
Other languages
English (en)
Inventor
Пьеретт Банкер
Эрик Юджин Борос
Скотт Говард Дикерсон
Истван Колдор
Сесилия С. Кобл
Майкл Толар Мартин
Стивен Мигер Спаркс
Стефен Эндрю Томсон
Original Assignee
ГЛАКСОСМИТКЛАЙН ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГЛАКСОСМИТКЛАЙН ЭлЭлСи filed Critical ГЛАКСОСМИТКЛАЙН ЭлЭлСи
Publication of EA201000391A1 publication Critical patent/EA201000391A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Это изобретение относится к новому соединению, представляющему собой ингибитор гликогенфосфорилазы, и его применению в лечении диабета и других связанных с ним состояний. Кроме того, данное изобретение относится к фармацевтической композиции, содержащей указанное соединение, и к способам получения этого соединения и фармацевтической композиции.
EA201000391A 2007-09-28 2008-09-25 Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция EA201000391A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97586207P 2007-09-28 2007-09-28
PCT/US2008/077624 WO2009045830A1 (en) 2007-09-28 2008-09-25 Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof

Publications (1)

Publication Number Publication Date
EA201000391A1 true EA201000391A1 (ru) 2010-10-29

Family

ID=40098462

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000391A EA201000391A1 (ru) 2007-09-28 2008-09-25 Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция

Country Status (16)

Country Link
US (1) US20100305207A1 (ru)
EP (1) EP2195287A1 (ru)
JP (1) JP2010540552A (ru)
KR (1) KR20100087300A (ru)
CN (1) CN101932557A (ru)
AU (1) AU2008309003A1 (ru)
BR (1) BRPI0817721A2 (ru)
CA (1) CA2701120A1 (ru)
CO (1) CO6270306A2 (ru)
CR (1) CR11398A (ru)
DO (1) DOP2010000075A (ru)
EA (1) EA201000391A1 (ru)
MA (1) MA31776B1 (ru)
MX (1) MX2010003440A (ru)
WO (1) WO2009045830A1 (ru)
ZA (1) ZA201002181B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR20140045511A (ko) 2011-07-29 2014-04-16 다이쇼 세이야꾸 가부시끼가이샤 아미딘 화합물 또는 그의 염
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP7307440B2 (ja) * 2019-12-06 2023-07-12 エスケイシー・カンパニー・リミテッド 光学レンズ用ジイソシアネート組成物およびその調製方法
WO2021122645A1 (en) 2019-12-20 2021-06-24 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
CA2238298A1 (en) * 1995-11-24 1997-06-19 Luca Francesco Raveglia Quinoline derivatives
AU735545B2 (en) * 1996-05-24 2001-07-12 Neurosearch A/S Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
AU2003258491A1 (en) * 2002-09-05 2004-03-29 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
JP2006507329A (ja) * 2002-11-21 2006-03-02 ニューロサーチ、アクティーゼルスカブ 新規アリールウレイド安息香酸誘導体及びその使用
RU2007119427A (ru) * 2004-11-09 2008-12-20 СмитКлайн Бичем Корпорейшн (US) Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе

Also Published As

Publication number Publication date
CR11398A (es) 2010-06-28
BRPI0817721A2 (pt) 2015-03-31
WO2009045830A1 (en) 2009-04-09
MX2010003440A (es) 2010-04-21
ZA201002181B (en) 2011-06-29
CA2701120A1 (en) 2009-04-09
AU2008309003A1 (en) 2009-04-09
CO6270306A2 (es) 2011-04-20
EP2195287A1 (en) 2010-06-16
KR20100087300A (ko) 2010-08-04
CN101932557A (zh) 2010-12-29
MA31776B1 (fr) 2010-10-01
DOP2010000075A (es) 2010-07-15
US20100305207A1 (en) 2010-12-02
JP2010540552A (ja) 2010-12-24

Similar Documents

Publication Publication Date Title
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
EA200870475A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
CY1109842T1 (el) Αναστολεις της αφυδρογονασης 11-β-υδροξυστεροειδων i
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
MY148496A (en) Dpp iv inhibitor formulations
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
BRPI0915084B8 (pt) composto, e, composição farmacêutica
MY153915A (en) Organic compounds
EA201100007A1 (ru) Производные хиноксалиндиона
EA200870514A1 (ru) Ацетиленовые гетероарильные соединения
EA200870515A1 (ru) Моноциклические гетероарильные соединения
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
EA201201623A1 (ru) Лечение диабета 2 типа
EA201000392A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
EA201171339A1 (ru) Способ снижения внутриглазного давления у людей
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии